ABSTRACT
INTRODUCTION
It is commonly experienced by clinicians involved in cancer treatment, especially for patients in the advanced and progressive phase of disease, that pain is not always adequately controlled, even when up-to-date treatment guidelines are followed. One of the most frequent causes of such difficulty relates to the observation that pain occurs in 80% of cancer patients in an advanced stage of disease and in 30% of cases with a high intensity of pain [1] . These pain fluctuations are often unexpected and unpredictable [1] . Sometimes, they can be due to predictable, although unavoidable, causes such as voluntary motor activity or automatic changes in sleeping position [2] .
In the last 20 years, the objective analysis of the clinical pathway in oncologic patients has allowed to identify, within these pain variations, a specific pain syndrome called breakthrough cancer pain (BTcP) by the international scientific community, also defined as intense episodic pain (dolore episodico intenso) by Italian physicians. BTcP is differentiated from background pain is increased [3] . Even today, the clinical approach to BTcP varies markedly among physicians, from a complete negation of the syndrome to its over-estimation. The primary objective of this paper was to provide clinicians and practitioners involved in treatment of cancer patients in different roles with a reasoned synthesis of the ongoing scientific debate on BTcP. The debate is dynamic, as inferred from the considerable body of literature annually produced at both international and national level, and from the numerous scientific meetings during congresses or single-topic meetings held each year. Our analysis aims at providing the basis for an optimal clinical approach to BTcP.
METHODS
This paper is the result of a debate among three Italian experts-two clinicians and a pharmacologist-operating in pain therapy and palliative care. The integration of an analysis of existing literature and clinical experience of the authors offers a rational and up-to-date support to all who are asked to provide an adequate treatment for pain to over 180,000 oncologic patients in Italy. Some of these are terminally ill cancer patients experiencing the so-called advanced and progressive stage of disease, no longer manageable with etiologic treatments. This article does not contain any new studies with human or animal subjects performed by any of the authors.
PATHOPHYSIOLOGY OF BTcP

Definitions of BTcP
Despite increasing availability of ever more accurate tools and studies, the clinical features and physiopathogenesis of BTcP remain unclear. Over time, numerous differing BTcP definitions have been reported in the literature. All of them, however, derive from the first definition of the clinical profile of BTcP described as ''a transitory flare of pain in the setting of chronic pain managed with opioid therapy'' [4] . In 1995, BTcP was described as ''an exacerbation of pain that occurs spontaneously or which accompanies a specific activity'' [5] .
More recently, BTcP has been defined as ''a pain of short duration, more or less intense, which breaks through the pain barrier provided by analgesic medications managing BP'' [6, 7] .
According to one of the more recent and comprehensive definitions, ''breakthrough pain is a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain'' [e.g., background pain controlled through an around-the-clock (ATC)
dosing, that is drug administration at fixed times] [2] . A year earlier, the idea of BTcP having a different causal mechanism than for BP was introduced: ''Breakthrough pain can be an exacerbation of the baseline pain OR it can be a pain with a different cause from that of the baseline pain'' [1] . According to pathogenetic interpretation, BTcP should no longer be considered a fluctuation or a sudden variation of BP, but a type of pain triggered by a different causal mechanism, superimposed on the preexisting mechanism causing BP.
The definition by Davies et al. [2] has been revised in recent publications [3, 8] . An Thus, according to previously reported considerations, BTcP cannot be recognized as a single nosological entity, but includes different and changing pathogenetic mechanisms justifying its sub-typing [3] .
BTcP: Clinical Characteristics and Prevalence
The poorly defined and variable clinical characteristics of BTcP, together with imprecise prevalence data, account for the discordant taxonomy for this type of pain. Data show that BTcP is present in 40-80% of patients, characterized by a rapid onset (\3 min), a short duration (median 30 min), and a daily frequency of 4-7 episodes/day [9] [10] [11] . The prevalence between 40% and 80% is inaccurate. Furthermore, the definitions ''rapid onset'' and ''short duration'' are both qualitative and the daily average frequency, between 4 and 7 episodes, is too wide.
For clinical purposes, representation of BTcP types is shown in Fig. 1 : BTcP is usually classified into a stimulus-independent or spontaneous BTcP, a stimulus-dependent or evoked BTcP and a BTcP related to the therapeutic approach or to procedural interventions [12] . Evoked BTcP may be volitional or non-volitional. Evoked volitional BTcP may be related to normally painful stimuli (e.g., pinprick, application of intense heat) or to stimuli that do not normally provoke pain (allodynia). The attribute ''non-volitional'' refers to mechanisms regulated by the autonomous nervous system, such as intestinal peristalsis, arterial pulsation, and body temperature.
As shown in Fig. 1 , one pain type originally traced to BTcP is closely related to the loss of antalgic efficacy caused by the end-of-dose effect; according to available data, this type of pain would account for 17-30% of episodes at first classified as BTcP [13] . In these patients, a pain exacerbation would be brought on by an inadequate treatment of BP, in terms of dose/ duration of efficacy/schedule of administration of medications used according to the ATC plan, at fixed times daily.
Zeppetella [13] , and most other authors, do not include end-of-dose pain episodes among BTcP, as a fundamental requirement of BTcP is that BP must be properly controlled. This type of pain is due to inadequate BP therapy and should be treated in different ways.
Fig. 1
Clinical types and characteristics of breakthrough cancer pain [12] . Reproduced with permission from Svendsen et al [12] Conversely, most authors include the incident pain in BTcP, characterized by a prevalence of The difficulty, not fully solved in clinical practice, is due to the incapability to distinguish a BP variation from an actual BTcP episode. Thus, therapeutic behaviors differ substantially; for example, some authors inappropriately treat all circadian flares of pain with rescue opioids, as BP fluctuations [8] .
BTcP: Pathogenesis
Pathogenesis underlying BTcP onset is probably heterogeneous. BTcP may depend on stimuli responsible for a sudden excess of afferent nerve impulses or on alterations originating in the somatosensory system [14] . BTcP pathogenetic hypotheses are shown in Table 2 .
A first possible mechanism involved in BTcP onset could be related to a transient increase in Table 1 APM classification of BTcP categories and sub-categories, related to the pathogenetic mechanisms
Types of BTcP Subtypes
Idiopathic or spontaneous pain:
The episodes are not related to an identifiable precipitant and so are unpredictable in nature N/a
Incident pain:
The episodes are related to an identifiable precipitant, and so are somewhat predictable
Volitional incident pain:
Brought on by a voluntary act (e.g., walking)
Non-volitional pain:
Brought on by an involuntary act (e.g., coughing)
Procedural pain:
Related to a therapeutic intervention (e.g., wound dressing) [16] . Silent nociceptors are located in the visceral system in large numbers, for example in the intestine, and so [18] .
Lastly, the occurrence of a sudden pain flare, even with BTcP characteristics, in an area different from the main neoplasm may be secondary to a metastatic localization.
PHARMACOLOGICAL ASPECTS AND BTcP
Among the administration routes used for fentanyl-the active substance mainly used for treating BTcP-the transmucosal routes (buccal, sublingual, or nasal) are the most common. Importantly, epithelial cells forming oral mucosa are not in contact with each other through tight junctions (typical intestinal and nasal mucosa junctions) but through desmosomes and hemidesmosomes, loose intercellular junctions which make the transport and flux of substances easier [19] .
In the oral cavity, we can find separate areas pertaining to the palatal mucosa, the gingival mucosa, the so-called buccal mucosa pertaining to the cheeks and the sublingual mucosa. Sublingual and buccal mucosae, not keratinized, better work for the absorption of substances; however, the greater thickness of the buccal mucosa, corresponding to 500-600 lm, reduces its permeability [19] . The reduced thickness and the high degree of permeability of the sublingual mucosa, compared to the buccal mucosa, make this area the most favorable for absorption of substances [19] .
A more thorough exploration of the multilayered epithelium lining the oral mucosa allows to distinguish the layer formed by the so-called prickle cells or spinous cells from which granules of phospholipid material are interposed and disseminated among the epithelial cells (Fig. 2) . The phospholipidic composition of this substance, although partly a barrier, helps to create a mobile intercellular space allowing the flow of substances [19] .
In short, two transit routes through the oral mucosa may be recognized for substances as well as for medications: the transcellular route, a pathway for liposoluble substances (such as fentanyl), able to pass through the cell membranes; and the paracellular route, preferred by more water-soluble substances, which flow through the intercellular phospholipid material (Fig. 3 ) [19] .
The number of medications administered orally that can take advantage of the transcellular route is limited because these substances must have certain physical and chemical properties dominated by a precise balance between water solubility and lipophilicity [20] .
An additional element implied in substance absorption through the oral mucosa is represented by saliva, which has multiple physiological functions. Salivary glands collectively produce more than 1 L of saliva per day. They are classified into major and minor salivary glands. The former are mainly responsible for the aqueous component of saliva, whereas the latter, and particularly the sublingual glands, are responsible for the viscous component of saliva, which is enriched in mucins [20] . [19] . Reproduced with permission from Campisi et al. [19] Fig. 2 Stratification of the oral mucosa [19] . Reproduced with permission from Campisi et al. [19] The Sublingual Administration Route A study carried out in 1998 reported that, although relatively more permeable than the buccal mucosa, the sublingual mucosa does not provide a suitable transmucosal administration route: the sublingual region is devoid of an underlying muscular reinforcement and support structure, which is present in the buccal mucosa and confers fixedness and firmness to the epithelium [20] . Furthermore, the sublingual epithelium is constantly washed by huge amounts of saliva that makes the persistence of the drugs under the tongue difficult. Thus, in accordance with this study, the sublingual mucosa, while ensuring a rapid onset of pharmacological action because of its high permeability and abundant blood supply, would offer an effective route of administration only for quickly absorbed medications [21] .
However, drug delivery can also be affected by the concentration of mucus in the saliva; when the medication adheres to mucus it does not undergo easy removal by saliva, but its contact with mucosa epithelium lasts longer and its absorption continues with more efficacy. Mucoadhesive substances have been formulated to block the medication at the sublingual level [22] .
A recent study showed that transmucosal administration efficiency is limited by factors that support the presence of free, and therefore ready to be swallowed, medication in the oral cavity [23] . Among these factors, salivary secretion in its aqueous component plays a major role as it causes the release of medication in the oral cavity. However, if the medication adheres to the mucosa, absorption is guaranteed and systemic exposure will be largely determined by the physical and chemical properties of the medication [23] .
It has been reported that buccal and sublingual fat may absorb buprenorphine, thus delaying its plasma level increase and half-life [24] . Since fentanyl shares similar lipophilic properties, it is possible that buccal fat retention occurs. However, to the best of our knowledge, this does not seem to be a major determinant in the absorption of oral transmucosal fentanyl.
Pharmacological Properties of Fentanyl
Pharmacodynamics
Fentanyl, a full l-opioid receptor agonist, is a synthetic opioid with rapid onset of action and short duration (indicated for BTcP) and with a potency 50-100 times greater than that of morphine. In oral transmucosal formulations, its analgesic efficacy, proportional to the plasma concentration, occurs at between 0.3 and 1.2 ng/mL of blood, while respiratory depression is observed at between 10 and 20 ng/mL [25] .
Pharmacokinetics
Fentanyl is a highly lipophilic molecule, Table 3 [25] [26] [27] [28] [29] [30] [31] [32] .
Buccal and Sublingual Formulations: Data From the Literature
A recently published review compared the pharmacokinetic profile of two different transmucosal formulations and an intranasal formulation of fentanyl (Actiq, Effentora, and Instanyl, respectively), emphasizing that the formulation should be selected according to patient needs, the evolution of pain, and to its onset and persistence [33] .
A study carried out in 2006 assessed the bioequivalence of equal doses of fentanyl via the buccal route when administered in four tablets of 100 lg or in a single tablet of 400 lg [34] . The study showed that 400 lg of Effentora in a single tablet and four Effentora tablets each of 100 lg, administered via the buccal route are not bioequivalent by virtue of the different absorption surfaces exposed [34] . In spite of this evidence, a study carried out in 2008 demonstrated the bioequivalence between buccal and sublingual use of Effentora in 400 lg tablets in healthy volunteers [35] . This is in contrast with the idea that if a medication with no mucoadhesive molecules is placed under the tongue, its absorption should be reduced versus buccal administration (Fig. 4a, b ) [35] .
Furthermore, the findings of this study could be considered valid only for the dosage of 400 lg and could not be extrapolated to other dosages; the bioequivalence refers only to 400 lg and the bioequivalence of other dosages would require confirmation in a clinical trial.
In agreement with this statement, a recent paper published in the New England Journal of Medicine by members of the US Food and Drug Administration shows that budeprion, the generic version of bupropion, was bioequivalent to the branded drug at the dosage of 150 mg, but not at the dosage of 300 mg, in fact suggesting that bioequivalence at different dosages should be demonstrated by clinical studies and not extrapolated [36] .
There are substantial differences between medications formulated for sublingual administration, such as Abstral, and buccal administration, such as Effentora. Unlike
Abstral, Effentora excipients do not include the mucoadhesives that give Abstral sublingual absorption capability; specifically, crosscarmellose, a powerful disintegrant improver of absorption with bio-mucoadhesive action, and the silicified microcrystalline cellulose, a tablet binder and, concurrently, an agent promoting disintegration and biomucoadhesion [37] .
Diversification of Therapeutic Approaches in BTcP
In 2009, specific recommendations for the management of BTcP including an algorithm for dose titration were published [2] . On lack of • The mucosally absorbed dose bypasses hepatic first-pass metabolism
• Rapid onset of action
• Can be used by patients who are unable to swallow or find medications difficult to swallow due to nausea/vomiting
• May be difficult for patients with dry mouth/mucositis
• Drug and delivery system may be ingested in saliva
• May be limited to lower doses [29] (ABSTRAL) 
The Intranasal Route
The intranasal route is another important noninvasive route for systemic administration and, like the oral transmucosal route, offers benefits of rapid absorption, absence of first-pass metabolism, and a rapid therapeutic response. The respiratory area around the inferior turbinate is the area of maximum absorption of medications due to its extended surface, high • The systemically absorbed dose bypasses hepatic first-pass metabolism
• Can be administered by caregivers
• Convenient
• Patients may require training in the correct administration technique for intranasal sprays
• Potential for application-site adverse effects including nasal irritation
• Potentially unsuitable for patients with colds or illnesses that result in changes to the nasal mucosa
• Quantity of drug absorbed may be variable
• Nasal drip or swallowing can affect absorption
• May be difficult for patients lacking manual dexterity
[32] (LAZANDA)
BTcP breakthrough cancer pain a ACTIQ is not indicated for use in pediatric patients permeability, and abundant vascularization [38] . The epithelium lining the nasal cavity consists of basal cells, ciliated cells and mucussecreting cells (''goblet cells''). Unlike the oral mucosa, the intercellular junctions are tight, restricting the passage of substances [38] . Transcellular and paracellular passage can be recognized.
The currently available spray formulation, Instanyl, in which the medication is passively absorbed, presents a limitation due to the variable amount of solution which enters the pharynx and then is swallowed. In an attempt to overcome this problem, a new formulation of fentanyl was devised in combination with pectin, a mucoadhesive polymer, which forms a gel in the nasal cavity and from which the active substance is released and absorbed. Hence, even in nasal transmucosal administration, systems based on the use of mucoadhesive substances have been developed to control and increase systemic absorption [38] .
PRACTICAL ASPECTS OF BTcP TREATMENT
General Premises
Clinical and pharmacological aspects, previously analyzed, are crucial to understand [35] . FBT fentanyl buccal tablet. Reproduced with permission from Darwish et al. [35] why in clinical practice an optimal therapeutic approach for BTcP should follow different rules and principles from those for BP. The analgesic therapy for BTcP should always be based on an integration of the two therapeutic schemes, for BP and BTcP. On the other hand, in BTcP treatment, several variables may influence the initial choice of the active substance to be used, the possible switch, and the administration route and method as well: characteristics of patient, family and support group (e.g., a professional caregiver), the composition of the care team, the therapeutic setting, and the organizational-management-economic and local regulatory framework, more broadly defined as ''context'' ( [43] . Table 4 should be considered in the clinical approach to BTcP. This type of ''global'' approach must be implemented in both phases of the clinical pathway: (a) in the initial phase of selection of the active substance and administration route; and (b) in the subsequent phases, characterized by the achievement of the optimal daily dosage, even in case of switching due to inefficacy, intolerance, or difficulty in administration. It should also be noted that the concept of opioid rotation or opioid switch has developed as part of BP treatment and has been more studied in that area [39] than in BTcP.
Specific Aspects
All variables listed in
The misperception that ROO-administration systems may be superimposed in clinical use as they all release an identical active molecule (fentanyl) is commonly held, and the idea that each product has its own specificity and appropriateness of use has not yet sufficiently disseminated. We need to arrive at a rational 
Patient
• See Table 6 2. Family unit • See Table 7 • Number of members with caregiver role
• Internal relational features of the family unit
• Relational features with the care team 3. Caregiver • See Table 7 • Family caregiver NSAIDs, for example, are associated with a large number of toxic effects [49] . In addition, morphine per os, even in its immediate-release preparations, has an average time required to achieve the peak intensity, significantly more prolonged than ROOs [50] . In the case of BP fluctuations, short-term oral morphine may find indications as a rescue medication, i.e., necessary to adjust the ATC treatment in relation to the circadian pain flares [39] . Its uncritical use, however, in the case of a clear presence of BTcP, exposes patients to some risks: Table 6 must be carefully taken into account.
In a patient with good cognitive functions and with reasonable motor activity (especially in the upper limbs and hands), the choice of route and system of administration should be based primarily on their preference. This has been shown to be feasible in clinical practice [53] . The patient should be informed and educated about the four routes (gingival fornix, sublingual mucosa, oral mucosa, and nasal mucosa) and the six existing systems [54] .
The time dedicated to patient training is balanced by an increased adhesion of the patient to the treatment scheme and by the reduced rates of inefficacy resulting from an incorrect use of the chosen system. It is also clear that systems with easier administration instructions have a greater guarantee of success in patients who are already stressed by daily pain and suffering. In a recent European multicenter study, the oral route was generally the most appreciated [53] .
A recent comparative study among three fentanyl ROOs (two oral transmucosal and one nasal), although enrolling a limited number of patients, showed that the use of a product specifically developed for sublingual use was the most appreciated by patients because of its mucoadhesivity, rapid dissolution, and rapid absorption [33] .
When using the oral route, patients should be advised that swallowing ROOs before complete dissolution should be avoided, to maximize the bioavailability and not to increase the dosage for a satisfactory analgesic effect. This may not be easy for the patient, as it means keeping one or more tablets without mucoadhesive properties fixed to the oral mucosa for at least 10-15 min, until a complete dissolution [33] [34] [35] .
The use of the ''stick'' system, first marketed in Italy in 2005, which sticks to the gingival fornix, may represent the preferred choice for some patients. The same consideration can be made for the two systems that release fentanyl via the nasal route (in aqueous solution or pectin), in which the greater rapidity of action is counterbalanced by the need to have a good level of skill on the part of the patient in the use and loading of the specific devices.
Another important aspect is to assess drugtaking capability during the education and first-prescription phase, recently defined as ''accessibility'' [33] . This applies particularly in relation to the technical specifications of the An additional variable to be borne in mind in the choice of medication is the ability of the patient to maintain the forced postures required (such as maintenance of the supine position) or a possible inability to assume a sitting or semisitting position.
Lastly, the methods of titration for the achievement of effective dose must be considered. Methods are specific for each ROO and used correctly in only 42% of the cases treated [3] . In fact, although some recent studies have sought to identify a proportional relationship between the dose of the ATC opioid used for BP and the initial dosage of ROO [55] , the general rule is to commence with the lowest available dosage of the chosen ROO and to gradually increase it until the effective dose is reached [52] . Such a procedure-''initial titration''-should be planned when switching to another ROO in the case of a progressive loss of efficacy, after checking that selfadministration had been performed correctly.
It is quite clear that this assumes a certain importance in the choice by the patient both during instruction and prescription phases of the different dosages used during titration for a quick attainment of the optimal dosage for BTcP control. The situation is different in the case of:
(a) patients with cognitive-relational problems, or (b) with motor activity difficulties, especially in the upper limbs and hands, or difficulty with coordination of the complex buccal motor activity, especially for those subjects characterized by automatic movements of buccal ejection of liquids and solids. Especially in the more advanced stages of the disease, but also in elderly subjects, unconscious motions of sucking or ejection of that introduced by others into their oral cavity may be present.
In the former kind of patients, selection and method of administration become significant and imply an operability that is always ''active'' for the therapeutic team and more and more The role of professional caregivers or family members increases with the worsening of the disease and the progressive loss of patient autonomy. If an active support role is not provided, the risk is an incorrect pain management during the day, with a consequent request for ''unscheduled'' home visits by the care teams (e.g., GP, palliative care team, or continuity of care service). In some cases, especially at night or in weekends, the uncontrolled pain crises can lead to unnecessary and inappropriate access to the Emergency Health Network (e.g., to the hospital emergency or the community emergency service). It is recommended that, even in the initial BTcP treatment prescription, physicians and nurses take into proper account some important variables (Table 7) .
Comparative studies on currently available products and their administration by caregivers or family members, and on their preferences and assessments, are lacking, but it can be argued that the initial choice of an effective product for BTcP treatment can be based on three main characteristics: The non-mandatory use of specific delivery devices and the rapidity of drug dissolution are two variables that, on a case-by-case basis, should be integrated, in a matrix model, with the other three characteristics described above (Table 8) .
Variables Involved in the Therapeutic Approach: The Care Team
The definition of health care team in the context of palliative care or pain therapy is very broad, especially due to the absence of national and regional reference standards. Differences are observed in reference to each setting (e.g., the hospice), among different settings, and, finally, in reference to the socalled ''intensity of care'', the number of direct accesses to the patient by team members in relation to a pre-defined unit of time (e.g., number of days with at least one home visit in relation to the total number of days of patient management) [56] .
The composition of the care team and the time available for direct and indirect activities or through their own personal prescription book. In these latter two cases, the patient and/or family member must purchase the product in the pharmacy, having no right to reimbursement by the Italian National Health Service (NHS).
In some situations, mostly in the public or private non-profit ''hospital-at-home'' model, present only in certain regions (e.g., in Lombardy), the care team can supply medications (including ROOs) directly to the patient at home, provided that the drugs are included in the regional and/or local pharmacy formulary, or purchased from the facility to which the palliative care unit belongs.
A first consequence of these limitations is that, where the specialist prescription is not direct but presented as a ''therapeutic recommendation'', the patient must have the medication or medications ''registered'' by the GP in the Italian NHS's prescription book. This is not always automatic since each practitioner has their own base of scientific opinions, knowledge, and experiences. Following the Law 38/2010 and related training projects, GPs have acquired a specific cultural basis in treating pain [57] . 
BRIEF RECOMMENDATIONS IN THE USE OF MEDICATIONS IN BTcP
The main points contained in the article are 
